Page 126 - Bioterrorism

125

<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,2g50,k3xg,4h4n,gyv>
, GlaxoSmithKline
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,4dxa,bgku,4h4n,gyv>
, Vaccine
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,ks8b,3xm5,4h4n,gyv>
, manufacturing
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,jjxm,m3jp,4h4n,gyv>

Novartis teams up on master's program
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,2bdk,i97g,4h4n,gyv>

By John Carroll

<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,1yhm,21aj,4h4n,gyv#comment>
Comment
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,1yhm,21aj,4h4n,gyv#comment>
|
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,9xzj,lm1b,4h4n,gyv>
Forward
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,9xzj,lm1b,4h4n,gyv>

Looking to cultivate some expert assistance for on-the-ground
vaccine research work, Novartis Vaccines and Diagnostics is partnering
with the University of Siena to offer a unique, two-year Masters
program covering the clinical development of vaccines for a group of
doctors from developing countries. Novartis will bring its scientific
know-how to the class, which will largely be made up of doctors from
African and Asian countries.

"The best place to develop a vaccine for developing countries is the
developing country," Dr. Giovanni Della Cioppa, head of Global
Clinical Research & Development for Novartis Vaccines, tells
FierceVaccines. Key factors like engineering a vaccine's resistance to
high temperatures and use of local storage facilities would be built
into the research programs, pushing the researchers to come up with
treatments that are ideal for that environment. And these new experts
on vaccine development will be free to work with any developers.

"For all of those interested in big-scale clinical research,
creating new centers of excellence outside of the normal, very
expensive environment of North America and Europe would be of great
interest," says Dr. Cioppa, who's been thinking about setting up a
program like this for the past decade.

"Clinical research and development of vaccines, along with
immunology, infectivology and biostatistics, are some of the core
subjects that will be addressed during the program," explains
Professor Ranuccio Nuti, coordinator of the Technical-Scientific
Committee. "Our aim is to provide these medical professionals with the
knowledge necessary to meet the demands arising in the area of
neglected diseases as well as to prepare them to react proactively to
situations such as the recent outbreak of the H1N1 virus in Mexico."

The first year of the program will cover immunology, infectivology,